Deloitte Cuts GLP-1 Weight-Loss Coverage for 181,000 US Staff
Deloitte will drop GLP-1 weight-loss coverage and raise deductibles for 181,000 US staff from January, as employer health costs climb and 39% of firms plan similar cuts.

Starting in January, Deloitte will stop covering GLP-1 medication for weight loss through its US medical plans, while raising deductibles and out-of-pocket maximums for roughly 181,000 employees. An internal benefits guide seen by Business Insider says most health plans will cost staff more both before and after coverage kicks in.
The Big Four firm framed the move as a cost necessity. The changes "reflect the hard trade-offs of today's cost environment," the document said, adding there was a need "for shared responsibility in a few specific places where it's become untenable for Deloitte to carry the cost alone."
A Deloitte spokesperson said that, like other large employers, the firm has made select modifications where cost growth rates are no longer sustainable. "Our financial commitment to our people and their families continues to grow," they said.
What stays covered — and what replaces it?
GLP-1s remain covered when prescribed for diabetes and other covered medical conditions. For weight loss, Deloitte is offering a virtual lifestyle program called eMed, which includes coaching and a $125-per-prescription employer contribution.
That's a thin cushion against list prices. Common GLP-1s such as semaglutide and tirzepatide generally list above $1,000, though direct purchase programs like LillyDirect and government plans like TrumpRx often charge far less — TrumpRx sells Ozempic-brand semaglutide injection pens for between $199 and $499. The spokesperson noted the new weight-related support includes direct-from-manufacturer drug pricing.
Not everything is shrinking. Deloitte is improving long-term disability protection and adding free annual eye exams to its company-paid discount vision program. The benefits guide applies to what Deloitte calls its "Core, Domain, and Enterprise professionals" — the majority of its traditional client-facing accountants, consultants, and technical specialists.
Is this part of a national trend?
Yes, and a measurable one. A 2026 KFF health benefits survey found workers on family plans paid an average of $7,471 a year in premiums — up 9% from 2025. Counting employer contributions, family premiums totaled $28,303, a roughly 5% increase. For a household, that's several hundred dollars more per year before a single deductible dollar.
GLP-1s are a particular pressure point. Insurance broker Aon found GLP-1 use rose 75% in 2025, and 39% of employers planned to reduce or restrict coverage in 2026. PwC and Starbucks have already pulled weight-loss coverage this year.
Deloitte has trimmed elsewhere too. In April, Business Insider reported that staff in its Center talent model — mostly internal-facing admin roles — would see parental leave, annual PTO, and IVF funding reduced or eliminated from January 1, 2027.
The backdrop is slowing growth: Deloitte's Americas division was its slowest-growing region globally in the financial year ending May 31, 2026, with revenue up 3.2%, down from 7.1% a year earlier.
If the 39% of employers planning GLP-1 restrictions follow through, fewer American workers will find weight-loss drugs in their benefits packets in 2027 — regardless of employer size.
Source: feeds.businessinsider.com
More from Grace Kim
Show full bio
Correspondent covering money, funding and market shifts around Job market data and labor economics at Path & Pay.
586 articles